Project dates: 2009-05-31 00:00:00 - 2011-06-30 00:00:00
This project will evaluate the potential of a new non-toxic adjuvant to elicit protection against genital and respiratory chlamydial infections using 3 needle-free methods of immunization. Chlamydia is the most common sexually transmitted infection and is associated with coronary artery disease and asthma. Proving that this adjuvant, CTA1-DD, is safe and effective will be a major step towards developing a vaccine to target human chlamydial infections. Vaccines delivered as intranasal or sublingual drops or as a patch applied directly to skin will not only aid compliance and ease of delivery but also more effectively target immunity to the reproductive and respiratory mucosae.
Funding / Grants
- Australian Research Council
- ARC Linkage - APAI or APDI - Biovitrum AB